About Actimis
Actimis is a Healthcare company based in San Diego (United States) founded in 2004, and was acquired by Boehringer Ingelheim in June 2008. Small molecule therapeutics for respiratory and inflammatory disorders. Actimis has raised $15.6 million across 2 funding rounds from investors including Boehringer Ingelheim, Sanderling Ventures and Mitsui Ventures. Its focus areas include Diversified Pharmaceuticals.
Company details
Actimis Pharmaceuticals is a privately held biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, chronic obstructive pulmonary disease, inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. Actimis was spun off from Bayer Healthcare AG in November 2004. It got acquired by Boehringer-Ingelheim in 2008.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website actimis.com
- Acquired by Boehringer Ingelheim (Jun 2008)
- Total Equity Funding$15.6M (USD)
in 2 rounds
- Latest Funding Round$9.6M (USD), Series B
Jun 2008
- InvestorsBoehringer Ingelheim
& 2 more
- Acquired byBoehringer Ingelheim
(Jun 2008)
Funding Insights of Actimis
Actimis has successfully raised a total of $15.6M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $9.6 million completed in June 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.6M
- Total Rounds 2
- Last Round Series B — $9.6M
- First Round $6M
(Apr 2005)
- Investors Count 2
All 2 funding rounds of Actimis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2008 | $9.6M | Series B | – | – | |
| Apr 2005 | $6M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Actimis
Actimis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Boehringer Ingelheim, Sanderling Ventures and Mitsui Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biomedical investment financing and active management services. | sanderling.com | |||
| mitsuiventures.com | ||||
Generic drugs and clinical research services are provided globally. | 1885 | boehringer-ingelheim.com |
Investor details for Actimis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Actimis
4 dated milestones of Actimis across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Actimis is founded.
- Funding First funding round of $6.0M.
- Funding Latest funding round, Series B, of $9.6M.
- Exit Acquired by Boehringer Ingelheim.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Actimis (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Actimis
Actimis was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Actimis is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Actimis is a funded company, having raised a total of $15.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Apr 2005.
Actimis Pharmaceuticals is a privately held biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, chronic obstructive pulmonary disease, inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. Actimis was spun off from Bayer Healthcare AG in November 2004. It got acquired by Boehringer-Ingelheim in 2008.
Actimis has 3 investors. Key investors include Boehringer Ingelheim, Sanderling Ventures, and Mitsui Ventures.
Yes. Actimis was acquired by Boehringer Ingelheim in June 2008.